Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

Core Insights - Creative Medical Technology Holdings, Inc. supports President Trump's executive order aimed at expanding access to in vitro fertilization (IVF), aligning with the company's vision to enhance reproductive health through its OvaStem program, which shows an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient's own eggs, with no safety concerns reported up to five years post-treatment [1][4]. Group 1: OvaStem Program - OvaStem provides a novel, personalized alternative to traditional IVF for patients with Primary Ovarian Insufficiency (POI), who typically have only a 5-10% chance of spontaneous pregnancy and often rely on donor eggs [2]. - The next-generation OvaStem integrates the AlloStem platform, which is currently utilized in two FDA-cleared U.S. clinical trials, and the company has filed for Orphan Drug Designation for POI, reinforcing its leadership in fertility innovation [2]. Group 2: Executive Order Impact - The executive order mandates the Domestic Policy Council to deliver recommendations within 90 days to lower out-of-pocket IVF costs, which currently range from $12,000 to $25,000 per cycle, making treatment inaccessible for many families [3]. - By removing financial barriers, the administration's plan is expected to facilitate greater adoption of advanced fertility technologies [3]. Group 3: Company Commitment - The company expresses its commitment to providing the safest, most effective, and affordable infertility solutions, positioning OvaStem at the forefront of the fertility care revolution [4]. - With a robust portfolio of proprietary technologies and clinical programs, the company aims to address pressing medical challenges and drive shareholder value as federal efforts to expand fertility care progress [4].